Milrinone
Milrinone (milrinone) is a small molecule pharmaceutical. Milrinone was first approved as Primacor on 1987-12-31. It is used to treat heart failure in the USA. The pharmaceutical is active against cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A. In addition, it is known to target cGMP-dependent 3',5'-cyclic phosphodiesterase, cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B, and cGMP-specific 3',5'-cyclic phosphodiesterase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
Trade Name
FDA
EMA
Milrinone (discontinued: Milrinone, Primacor)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| milrinone lactate | ANDA | 2024-01-10 |
| milrinone lactate in dextrose | ANDA | 2022-03-28 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| heart failure | HP_0001635 | D006333 | I50 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2260 | Injection, milrinone lactate, 5 mg |
Clinical
Clinical Trials
75 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | HP_0001635 | I50 | 5 | 7 | — | 1 | 8 | 18 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 2 | 5 | 3 | 1 | 3 | 12 |
| Hypertension | D006973 | EFO_0000537 | I10 | 2 | 3 | 3 | 1 | 4 | 11 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | 1 | 1 | — | 1 | 6 | 9 |
| Cardiogenic shock | D012770 | — | R57.0 | 1 | 1 | — | 3 | 3 | 8 |
| Shock | D012769 | — | R57.1 | — | 1 | — | 3 | 3 | 7 |
| Low cardiac output | D002303 | — | — | 1 | 2 | 2 | 1 | 2 | 7 |
| Syndrome | D013577 | — | — | — | 2 | 2 | 1 | 1 | 6 |
| Intracranial vasospasm | D020301 | EFO_1000994 | G45.9 | — | 1 | 1 | 1 | 1 | 4 |
| Septic shock | D012772 | — | A48.3 | — | 1 | — | 1 | 1 | 3 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhage | D006470 | MP_0001914 | R58 | — | 3 | 1 | — | 2 | 6 |
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | 3 | 1 | — | 1 | 5 |
| Pulmonary arterial hypertension | D000081029 | — | — | — | — | 1 | — | 1 | 2 |
| Cardiac surgical procedures | D006348 | — | — | — | — | 1 | — | 1 | 2 |
| Mitral valve insufficiency | D008944 | HP_0001653 | — | — | — | 1 | — | — | 1 |
| Respiratory aspiration | D053120 | EFO_1001839 | — | — | 1 | 1 | — | — | 1 |
| Vasodilation | D014664 | — | — | — | — | 1 | — | — | 1 |
| Newborn infant diseases | D007232 | — | — | — | — | 1 | — | — | 1 |
| Familial primary pulmonary hypertension | D065627 | — | I27.0 | — | — | 1 | — | — | 1 |
| Hereditary congenital and neonatal diseases and abnormalities | D009358 | — | — | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | — | 3 | — | — | 3 | 6 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | 1 | — | — | 2 | 3 |
| Right ventricular dysfunction | D018497 | — | — | 1 | 1 | — | — | 1 | 3 |
| Ventricular dysfunction | D018754 | — | — | 1 | 1 | — | — | 1 | 3 |
| Persistent fetal circulation syndrome | D010547 | EFO_1001103 | P29.3 | — | 1 | — | — | 2 | 3 |
| Coronary artery disease | D003324 | — | I25.1 | — | 1 | — | — | 2 | 3 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | 1 | — | — | 1 | 2 |
| Healthy volunteers/patients | — | — | — | 1 | 1 | — | — | 1 | 2 |
| Ischemia | D007511 | EFO_0000556 | — | — | 1 | — | — | — | 1 |
| Cerebral infarction | D002544 | — | I63 | — | 1 | — | — | — | 1 |
Show 18 more
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | — | 2 | 2 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 2 | 2 |
| Covid-19 | D000086382 | — | — | — | — | — | — | 1 | 1 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 1 | 1 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | — | — | — | 1 | 1 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 1 | 1 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | — | 1 | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | — | — | — | 1 | 1 |
| Pneumonia | D011014 | EFO_0003106 | — | — | — | — | — | 1 | 1 |
Show 38 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Milrinone |
| INN | milrinone |
| Description | Milrinone is a member of the class of bipyridines that is 2-pyridone which is substituted at positions 3, 5, and 6 by cyano, pyrid-4-yl, and methyl groups, respectively. It is used (particularly intravenously, as the lactate) for the short-term management of severe heart failure. It has a role as an EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor, a platelet aggregation inhibitor, a vasodilator agent and a cardiotonic drug. It is a pyridone, a nitrile and a member of bipyridines. |
| Classification | Small molecule |
| Drug class | cardiotonics (amrinone type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1 |
Identifiers
| PDB | — |
| CAS-ID | 78415-72-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL189 |
| ChEBI ID | 50693 |
| PubChem CID | 4197 |
| DrugBank | DB00235 |
| UNII ID | JU9YAX04C7 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
PDE2A
PDE2A
PDE3B
PDE3B
TTR
TTR
Organism
Homo sapiens
Gene name
PDE2A
Gene synonyms
NCBI Gene ID
Protein name
cGMP-dependent 3',5'-cyclic phosphodiesterase
Protein synonyms
cGMP-stimulated phosphodiesterase 1, cGMP-stimulated phosphodiesterase 2, cGMP-stimulated phosphodiesterase 4, CGS-PDE, cGSPDE, Cyclic GMP-stimulated phosphodiesterase, phosphodiesterase 2A, cGMP-stimulated
Uniprot ID
Mouse ortholog
Pde2a (207728)
cGMP-dependent 3',5'-cyclic phosphodiesterase (Q922S4)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,980 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
877 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use